Comgest Global Investors S.A.S. Has $212.74 Million Holdings in Zoetis Inc. $ZTS

Comgest Global Investors S.A.S. increased its position in Zoetis Inc. (NYSE:ZTS) by 2.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,453,966 shares of the company’s stock after buying an additional 36,238 shares during the period. Zoetis accounts for 3.8% of Comgest Global Investors S.A.S.’s portfolio, making the stock its 10th largest holding. Comgest Global Investors S.A.S.’s holdings in Zoetis were worth $212,744,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in ZTS. Vanguard Group Inc. raised its holdings in Zoetis by 1.0% during the third quarter. Vanguard Group Inc. now owns 42,306,764 shares of the company’s stock valued at $6,190,326,000 after buying an additional 419,777 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Zoetis by 0.9% during the 2nd quarter. Geode Capital Management LLC now owns 11,081,301 shares of the company’s stock valued at $1,721,356,000 after acquiring an additional 95,294 shares during the last quarter. Norges Bank acquired a new position in shares of Zoetis during the 2nd quarter valued at about $809,491,000. Brown Advisory Inc. raised its stake in shares of Zoetis by 5.7% in the 2nd quarter. Brown Advisory Inc. now owns 4,659,371 shares of the company’s stock valued at $726,629,000 after acquiring an additional 250,829 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in Zoetis by 113.0% in the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,761,920 shares of the company’s stock worth $586,671,000 after purchasing an additional 1,995,491 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Up 2.9%

Shares of ZTS opened at $129.17 on Thursday. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. The company has a 50-day simple moving average of $125.01 and a 200-day simple moving average of $135.02. Zoetis Inc. has a 52 week low of $115.25 and a 52 week high of $177.00. The firm has a market capitalization of $54.53 billion, a P/E ratio of 21.46, a P/E/G ratio of 1.92 and a beta of 0.96.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. The firm had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, equities research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 1.6%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is 35.22%.

Analysts Set New Price Targets

ZTS has been the topic of several analyst reports. Wall Street Zen upgraded Zoetis from a “hold” rating to a “buy” rating in a report on Friday, January 23rd. The Goldman Sachs Group upgraded shares of Zoetis to a “buy” rating in a research note on Monday, December 15th. Bank of America lifted their target price on shares of Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a report on Friday, February 13th. UBS Group set a $136.00 price target on shares of Zoetis in a report on Thursday, January 29th. Finally, BTIG Research reiterated a “buy” rating and issued a $160.00 price objective on shares of Zoetis in a research note on Wednesday, December 3rd. Five research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $152.91.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.